Floatz logo

Nicotine

Cognitive Disorder

University of Southern CaliforniaSmall moleculePhase 2Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

132 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB
Rivastigmine
VA Office of Research and Development
Phase 4BB
Levodopa
Vanderbilt University Medical Center
Phase 4BB
QUETIAPINE
Emory University
Phase 4BB

View all 50 →

Same molecule, other indications

Nicotine is also rated in:

nicotine dependenceActive
A
Indicative · Phase 4
83 / 100
View asset →
schizophreniaActive
BB
Indicative · Phase 4
71 / 100
View asset →
schizoaffective disorderActive
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →